Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Erlotinib With or Without Hydroxychloroquine in Patients With Previously Untreated Advanced NSCLC and EGFR Mutations

NCT00977470 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00977470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00977470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Erlotinib With or Without Hydroxychloroquine in Patients With Previously Untreated Advanced NSCLC and EGFR Mutations
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 31, 2009
Completion date
December 31, 2027
Enrollment
76 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer